Advertisement

Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis

Published:February 17, 2015DOI:https://doi.org/10.1016/j.pcd.2015.01.011

      Highlights

      • Persistence of basal insulin use in type 2 diabetes patients was described.
      • Risk factors for poor persistence was determined.
      • Treatment with insulin glargin was associated with lower discontinuation.
      • Metformin und sulfonylurea comedication were predictors for better persistence.

      Abstract

      Aims

      To compare persistence and its predictors in type 2 diabetes patients in primary care, initiating either basal supported oral therapy (BOT) or intensified conventional therapy (ICT) with glargine, detemir, or NPH insulin.

      Methods

      In the BOT cohort, 1398 glargine (mean age: 68 years), 292 detemir (66 years), and 874 NPH (65 years) users from 918 practices were retrospectively analyzed (Disease Analyzer, Germany: 2008–2012). The ICT group incorporated 866 glargine (64 years), 512 detemir (60 years), and 1794 NPH (64 years) new users. Persistence was defined as proportion of patients remaining on the initial basal insulin (glargine, detemir and NPH insulin) over 2 years. Persistence was evaluated by Kaplan–Meier curves (log-rank tests) and Cox regression adjusting for age, sex, diabetes duration, antidiabetic co-therapy, comorbidities, specialist care, and private health insurance.

      Results

      In BOT, two-year persistence was 65%, 53%, and 59% in glargine, detemir, and NPH users, respectively (p < 0.001). In ICT, persistence was higher without differences between groups: 84%, 85%, 86% in glargine, detemir, and NPH, respectively (p = 0.536). In BOT, detemir and NPH users were more likely to discontinue basal insulin compared with glargine (detemir vs. glargine: adjusted Hazard Ratio; 95% CI: 1.56; 1.31–1.87; NPH vs. glargine: 1.22; 1.07–1.38). Heart failure (1.39; 1.16–1.67) was another predictor of non-persistence, whereas higher age (per year: 0.99; 0.98–0.99), metformin (0.61; 0.54–0.69), and sulfonylurea co-medication (0.86; 0.77–0.97) were associated with lower discontinuation.

      Conclusions

      In BOT, treatment persistence among type 2 diabetes patients initiating basal insulin is influenced by type of insulin, antidiabetic co-medication, and patient characteristics.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • UK Prospective Diabetes Study (UKPDS) Group
        Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • Inzucchi S.E.
        • Bergenstal R.M.
        • Buse J.B.
        • Diamant M.
        • Ferrannini E.
        • Nauck M.
        • Peters A.L.
        • Tsapas A.
        • Wender R.
        • Matthews D.R.
        Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetologia. 2012; 55: 1577-1596
        • Swinnen S.G.
        • Simon A.C.
        • Holleman F.
        • Hoekstra J.B.
        • Devries J.H.
        Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
        Cochrane Database Syst. Rev. 2011; 7: CD006383
        • Institute for Quality and Efficiency in Health Care
        Long-acting insulin analogues in the treatment of type 2 diabetes. Executive summary of final report A05-03. Version 1.1.
        2009 (accessed 11.06.14)
        • Cramer J.A.
        A systematic review of adherence with medications for diabetes.
        Diabetes Care. 2004; 27: 1218-1224
        • Cramer J.A.
        • Roy A.
        • Burrell A.
        • et al.
        Medication compliance and persistence: terminology and definitions.
        Value Health. 2008; 11: 44-47
        • Wei W.
        • Zhou S.
        • Miao R.
        • Pan C.
        • Xie L.
        • Baser O.
        • Gill J.
        Much ado about nothing? A real-world study of patients with type 2 diabetes switching basal insulin analogs.
        Adv. Ther. 2014; 31: 539-560
        • Borah B.J.
        • Darkow T.
        • Bouchard J.
        • Aagren M.
        • Forma F.
        • Alemayehu B.
        A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
        Clin. Ther. 2009; 31: 623-631
        • Becher H.
        • Kostev K.
        • Schröder-Bernhardi D.
        Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies.
        Int. J. Clin. Pharmacol. Ther. 2009; 47: 617-626
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • et al.
        Coding algorithms for defining co-morbidities in ICD-9-CM and ICD-10 administrative data.
        Med. Care. 2005; 43: 1130-1139
        • Swart E.
        Good practice of secondary data analysis, first revision.
        Gesundheitswesen. 2008; 70: 54-60
        • Motheral B.
        • Brooks J.
        • Clark M.A.
        • et al.
        A checklist for retrospective database studies – report from the ISPOR task force on retrospective databases.
        Value Health. 2003; 6: 90-97
        • Wei W.
        • Pan C.
        • Xie L.
        • Baser O.
        Real-world insulin treatment persistence among patients with type 2 diabetes.
        Endocr. Pract. 2014; 20: 52-61
        • Davis K.L.
        • Tangirala M.
        • Meyers J.L.
        • Wei W.
        Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
        Curr. Med. Res. Opin. 2013; 29: 1083-1091
        • Quinzler R.
        • Ude M.
        • Franzmann A.
        • Feldt S.
        • Schüssel K.
        • Leuner K.
        • Müller W.E.
        • Dippel F.W.
        • Schulz M.
        Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
        Int. J. Clin. Pharmacol. Ther. 2012; 50: 24-32
        • Pfohl M.
        • Dippel F.W.
        • Kostev K.
        • Fuchs S.
        • Kotowa W.
        Different persistence on initial basal supported oral therapy in type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany.
        Int. J. Clin. Pharmacol. Ther. 2010; 48: 761-766
        • Eliasson B.
        • Ekström N.
        • Bruce Wirta S.
        • Odén A.
        • Fard M.P.
        • Svensson A.M.
        Metabolic effects of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice.
        Diabetes Ther. 2014; (May 15 (Epub ahead of print))
        • Rathmann W.
        • Dippel F.W.
        • Kostev K.
        Different injection frequencies of basal insulins in type 2 diabetes patients under real-life conditions: a retrospective database analysis.
        J. Diabetes Sci. Technol. 2013; 7: 1354-1358
        • Nikolaidis L.A.
        • Sturzu A.
        • Stolarski C.
        • Elahi D.
        • Shen Y.T.
        • Shannon R.P.
        The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.
        Cardiovasc. Res. 2004; 61: 297-306
        • Uriel N.
        • Naka Y.
        • Colombo P.C.
        • Farr M.
        • Pak S.W.
        • Cotarlan V.
        • Albu J.B.
        • Gallagher D.
        • Mancini D.
        • Ginsberg H.N.
        • Jorde U.P.
        Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices.
        Eur. J. Heart Fail. 2011; 13: 195-199
        • Holden S.E.
        • Currie C.J.
        Mortality risk with sulphonylureas compared to metformin.
        Diabetes Obes. Metab. 2014; https://doi.org/10.1111/dom.12280
        • Phung O.J.
        • Schwartzman E.
        • Allen R.W.
        • Engel S.S.
        • Rajpathak S.N.
        Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.
        Diabet. Med. 2013; 30: 1160-1171